<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Using unrelated bone marrow, there is an increased risk of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: HLA-A-, HLA-B-, and HLA-DR-compatible unrelated bone marrow was given to 132 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The diagnoses included <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=43), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n=29), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=27), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=4), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=3), <z:mp ids='MP_0009440'>myeloma</z:mp> (n=1), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n=1), severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n=12), and <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> (n=12) </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 25 years (range 1-55 years) </plain></SENT>
<SENT sid="4" pm="."><plain>HLA class I was typed serologically, and class II was typed by polymerase chain reaction using sequence-specific primer pairs </plain></SENT>
<SENT sid="5" pm="."><plain>Immunosuppression consisted of antithymocyte globulin or OKT3 for 5 days before transplantation and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> combined with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Engraftment was seen in 127 of 132 patients (96%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">Bacteremia</z:e> occurred in 47%, cytomegalovirus (CMV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in 49%, and CMV disease in 8% </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative incidences of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD &gt; or = grade II and of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were 23% and 50%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The 5-year transplant-related mortality rate was 39% </plain></SENT>
<SENT sid="10" pm="."><plain>The overall 5-year patient survival rate was 49%; in patients with <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, it was 61% and 48%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The disease-free survival rate was 47% in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> in first remission or first <z:hpo ids='HP_0011010'>chronic</z:hpo> phase and 38% in patients with more advanced disease (P=0.04) </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD was associated with early engraftment of white blood count (P=0.02) </plain></SENT>
<SENT sid="13" pm="."><plain>Poor outcome in multivariate analysis was associated with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (P=0.01) and CMV disease (P=0.04) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Using HLA-A-, HLA-B-, and HLA-DR-compatible unrelated bone marrow and immunosuppression with antithymocyte globulin, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, the probability of GVHD was low and survival was favorable </plain></SENT>
</text></document>